Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion Criteria~* Diagnosis of advanced or metastatic NSCLC. Group A must be ALK negative NSCLC and Group B must be ALK positive NSCLC~* Group A at least one prior regimen of therapy~* Group B any number of prior regimens.~* Mandatory tumor tissue available~* At least one measurable lesion~* ECOG Performance status 0 or 1~* Adequate bone marrow, renal, liver and pancreatic function~* Negative pregnancy test for females of childbearing potential~* Group B Phase 2: No prior systemic treatment for advanced or metastatic disease (adjuvant and/or neoadjuvant therapies are allowed if completed at least 6 months prior to study entry. No prior tyrosine kinase inhibitor therapy is allowed at any time prior to study entry)~Exclusion Criteria:~* No prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody.~* No Severe or Chronic medical conditions including gastrointestinal abnormalities or significant cardiac history~* No active infection requiring systemic therapy~* Prior organ transplantation including allogenic stem cell transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): ALK negative Non-Small Cell Lung Cancer
- Group B (Type: EXPERIMENTAL): ALK positive Non-Small Cell Lung Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).